PL1830924T3 - Zapobieganie tworzeniu i/lub stabilizacji skrzepu - Google Patents
Zapobieganie tworzeniu i/lub stabilizacji skrzepuInfo
- Publication number
- PL1830924T3 PL1830924T3 PL05820601T PL05820601T PL1830924T3 PL 1830924 T3 PL1830924 T3 PL 1830924T3 PL 05820601 T PL05820601 T PL 05820601T PL 05820601 T PL05820601 T PL 05820601T PL 1830924 T3 PL1830924 T3 PL 1830924T3
- Authority
- PL
- Poland
- Prior art keywords
- stabilization
- prevention
- thrombus formation
- thrombus
- formation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04030593 | 2004-12-23 | ||
PCT/EP2005/013714 WO2006066878A1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
EP05820601A EP1830924B1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1830924T3 true PL1830924T3 (pl) | 2013-08-30 |
Family
ID=34927953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL05820601T PL1830924T3 (pl) | 2004-12-23 | 2005-12-20 | Zapobieganie tworzeniu i/lub stabilizacji skrzepu |
Country Status (14)
Country | Link |
---|---|
US (3) | US8119137B2 (pl) |
EP (2) | EP2272565A3 (pl) |
JP (1) | JP5118492B2 (pl) |
KR (1) | KR101277097B1 (pl) |
CN (1) | CN101102819A (pl) |
AU (1) | AU2005318464B2 (pl) |
BR (1) | BRPI0519349A8 (pl) |
CA (1) | CA2591786C (pl) |
DK (1) | DK1830924T3 (pl) |
ES (1) | ES2407965T3 (pl) |
MX (1) | MX2007006997A (pl) |
PL (1) | PL1830924T3 (pl) |
RU (1) | RU2514878C2 (pl) |
WO (1) | WO2006066878A1 (pl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
CA2488558C (en) | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
DK2386310T3 (en) | 2002-08-28 | 2019-02-25 | Dyax Corp | Methods of preserving organs and tissues |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
CA2658523C (en) | 2006-07-31 | 2012-06-12 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
EP2109457B1 (en) * | 2007-02-12 | 2016-01-06 | CSL Behring GmbH | Therapeutic application of kazal-type serine protease inhibitors |
CA2695012A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
AU2008315938B2 (en) * | 2007-10-22 | 2014-11-27 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
EP2103311A1 (en) | 2008-03-20 | 2009-09-23 | CSL Behring GmbH | The calcium sensor STIM1 is essential for pathological thrombus formation |
EP2145900A1 (en) | 2008-07-15 | 2010-01-20 | CSL Behring GmbH | Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation |
WO2010080833A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
EP2269597A1 (en) | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
EP2272874A1 (en) | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
SI2521568T1 (sl) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
US9150864B2 (en) * | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
IL269565B2 (en) | 2011-01-06 | 2024-06-01 | Dyax Corp | KALLIKREIN PLASMA BINDING PROTEINS |
EP2497489A1 (en) | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
WO2012120128A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
CN103687878B (zh) * | 2011-07-22 | 2018-01-09 | 德国杰特贝林生物制品有限公司 | 抑制性的抗因子xii/xiia单克隆抗体及其用途 |
EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
US20140296146A1 (en) * | 2011-08-23 | 2014-10-02 | Synapse B.V. | Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces |
EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
US9574013B2 (en) * | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
AU2014224599B2 (en) | 2013-03-08 | 2018-11-08 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
JP2017501968A (ja) * | 2013-06-28 | 2017-01-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第xii因子インヒビターおよびc1−インヒビターを使用する組合せ療法 |
US20170114119A1 (en) * | 2014-06-18 | 2017-04-27 | Csl Behring Gmbh | Therapy using a factor xii inhibitor in a neurotraumatic disorder |
AU2015373910B2 (en) | 2015-01-02 | 2021-11-18 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and factor XII |
CA2982413A1 (en) * | 2015-04-28 | 2016-11-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel inhibitors of the enzyme activated factor xii (fxiia) |
IL257047B1 (en) | 2015-07-21 | 2024-07-01 | Dyax Corp | A monoclonal antibody that inhibits factor XIIA |
JP7003354B2 (ja) | 2015-12-11 | 2022-03-04 | 武田薬品工業株式会社 | 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途 |
EP3440107A4 (en) | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
US11505619B2 (en) | 2017-12-15 | 2022-11-22 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
CA3104470A1 (en) * | 2018-06-19 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Anti-factor xii/xiia antibodies and uses thereof |
EP3886982A1 (en) * | 2018-11-28 | 2021-10-06 | Oregon Health & Science University | Therapeutic factor xii antibody |
CA3145299A1 (en) | 2019-07-08 | 2021-01-14 | Rezolute, Inc. | Processes for preparing plasma kallikrein inhibitors |
JP7088892B2 (ja) | 2019-10-11 | 2022-06-21 | イビデン株式会社 | 組電池用断熱シート及び組電池 |
WO2021253662A1 (zh) * | 2020-06-16 | 2021-12-23 | 宁波康善生物科技有限公司 | 抗fxii纳米抗体或其抗原结合片段及其应用 |
TW202242111A (zh) | 2020-12-18 | 2022-11-01 | 美商Ionis製藥公司 | 用於調節因子xii之化合物及方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK225488D0 (da) * | 1988-04-26 | 1988-04-26 | Novo Industri As | Polypeptid |
US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
WO1994020535A1 (en) * | 1992-12-11 | 1994-09-15 | Corvas International, Inc. | ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR |
JP3929484B2 (ja) | 1993-09-14 | 2007-06-13 | ジェネンテック・インコーポレーテッド | エコチンおよびその同族体を含む医薬的組成物 |
ZA963619B (en) * | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
US20030109680A1 (en) * | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
DE19725014A1 (de) * | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
DE69919702T2 (de) * | 1998-06-08 | 2005-09-15 | The University Of Vermont And State Agricultural College | Verfahren zur Bestimmung der Blutgerinnung in Plasma |
AU760735B2 (en) * | 1998-09-28 | 2003-05-22 | Merck & Co., Inc. | A method for treating inflammatory diseases by administering a thrombin inhibitor |
EP1222929B8 (en) * | 2001-01-11 | 2010-07-07 | Life Sciences Research Partners VZW | Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome |
CA2488558C (en) * | 2002-06-07 | 2013-08-20 | Dyax Corp. | Prevention and reduction of blood loss |
US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
US20060093595A1 (en) | 2002-07-05 | 2006-05-04 | Mahesh Jayachandra | Methods, compositions and kits for treating damage to excitable tissue |
DK2386310T3 (en) * | 2002-08-28 | 2019-02-25 | Dyax Corp | Methods of preserving organs and tissues |
US20040229778A1 (en) * | 2003-05-13 | 2004-11-18 | Elmaleh David R. | Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases |
WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
PL1626736T3 (pl) | 2003-05-16 | 2021-05-04 | Pharming Intellectual Property B.V. | Inhibitor c1 o krótkim okresie półtrwania do leczenia przejściowego |
US8152750B2 (en) * | 2003-09-12 | 2012-04-10 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
GB0411145D0 (en) | 2004-05-19 | 2004-06-23 | Imp College Innovations Ltd | Protease inhibitors and their therapeutic applications |
US8569277B2 (en) * | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
GB0418877D0 (en) | 2004-08-24 | 2004-09-29 | Univ Edinburgh | Heart |
US20060104944A1 (en) * | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
ES2346755T3 (es) | 2004-12-01 | 2010-10-20 | Par Pharmaceuticals, Inc. | Uso de acetato de megestrol para mejorar la funcion cardiaca y el tratamiento de la insuficiencia cardiaca. |
-
2005
- 2005-12-20 KR KR1020077016992A patent/KR101277097B1/ko active IP Right Grant
- 2005-12-20 EP EP10183075A patent/EP2272565A3/en not_active Withdrawn
- 2005-12-20 CN CNA2005800465756A patent/CN101102819A/zh active Pending
- 2005-12-20 CA CA2591786A patent/CA2591786C/en active Active
- 2005-12-20 US US11/793,820 patent/US8119137B2/en active Active
- 2005-12-20 AU AU2005318464A patent/AU2005318464B2/en active Active
- 2005-12-20 WO PCT/EP2005/013714 patent/WO2006066878A1/en active Application Filing
- 2005-12-20 BR BRPI0519349A patent/BRPI0519349A8/pt not_active Application Discontinuation
- 2005-12-20 RU RU2007123797/14A patent/RU2514878C2/ru not_active Application Discontinuation
- 2005-12-20 DK DK05820601.2T patent/DK1830924T3/da active
- 2005-12-20 MX MX2007006997A patent/MX2007006997A/es active IP Right Grant
- 2005-12-20 PL PL05820601T patent/PL1830924T3/pl unknown
- 2005-12-20 ES ES05820601T patent/ES2407965T3/es active Active
- 2005-12-20 JP JP2007547323A patent/JP5118492B2/ja active Active
- 2005-12-20 EP EP05820601A patent/EP1830924B1/en active Active
-
2011
- 2011-12-29 US US13/339,793 patent/US20120148688A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/723,847 patent/US8715672B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK1830924T3 (da) | 2013-05-21 |
US8715672B2 (en) | 2014-05-06 |
WO2006066878A1 (en) | 2006-06-29 |
AU2005318464A1 (en) | 2006-06-29 |
US20080254039A1 (en) | 2008-10-16 |
US8119137B2 (en) | 2012-02-21 |
CA2591786A1 (en) | 2006-06-29 |
AU2005318464B2 (en) | 2012-02-23 |
EP2272565A2 (en) | 2011-01-12 |
MX2007006997A (es) | 2007-10-10 |
JP5118492B2 (ja) | 2013-01-16 |
EP1830924A1 (en) | 2007-09-12 |
BRPI0519349A8 (pt) | 2017-09-12 |
BRPI0519349A2 (pt) | 2009-01-20 |
RU2007123797A (ru) | 2009-01-10 |
EP2272565A3 (en) | 2012-03-28 |
EP1830924B1 (en) | 2013-02-27 |
CN101102819A (zh) | 2008-01-09 |
KR101277097B1 (ko) | 2013-06-20 |
CA2591786C (en) | 2013-07-16 |
US20120148688A1 (en) | 2012-06-14 |
JP2008525342A (ja) | 2008-07-17 |
RU2514878C2 (ru) | 2014-05-10 |
US20130164301A1 (en) | 2013-06-27 |
ES2407965T3 (es) | 2013-06-17 |
KR20070092303A (ko) | 2007-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL1830924T3 (pl) | Zapobieganie tworzeniu i/lub stabilizacji skrzepu | |
AP2007004245A0 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
IL188832A0 (en) | Systems and methods for stabilization of bone structures | |
EP1744744A4 (en) | BIOACTIVE COMPOUNDS AND METHODS OF USE THEREOF | |
EP1617805A4 (en) | METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS | |
HK1152474A1 (en) | Methods and compositions for the prevention and treatment of sepsis | |
IL209849A0 (en) | Sclerostin and the inhibition of wnt signaling and bone formation | |
IL182203A0 (en) | Thiadiazole compounds and methods of use | |
IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
HK1118186A1 (en) | Osteosynthetic implants and methods of use and manufacture | |
IL182734A0 (en) | 4-aminotetracyclines and methods of use thereof | |
HK1107503A1 (en) | Cheese and methods of making such cheese | |
GB0610350D0 (en) | prevention and/or treatment of neuodegenerative disorders | |
IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
EP1865972A4 (en) | TREATMENT OR PREVENTION OF CANCER AND PRECANCEROUS DISORDERS | |
EP2135078A4 (en) | METHODS OF IDENTIFYING AGENTS AND THEIR USE IN PREVENTING OR STABILIZING FIBROSIS | |
IL174577A0 (en) | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions | |
GB0404656D0 (en) | Treatment of spinal conditions | |
EP1833509A4 (en) | DELAYING OR PREVENTING THE APPEARANCE OF MULTIPLE SCLEROSIS | |
EP1812451A4 (en) | COMPOUNDS AND METHODS OF USE THEREOF | |
EP1817039A4 (en) | TREATMENT AND PREVENTION OF EPILEPSY | |
PL1773122T3 (pl) | Zastosowanie orto-fenylofenolu i/lub jego pochodnych do zahamowania bezpłciowego rozmnażania grzybów | |
GB0504657D0 (en) | Compositions and methods of treatment | |
IL166083A0 (en) | Methods for treatment and prevention of gastrointestinal conditions | |
IL165870A0 (en) | Use of chymase inhibitors for the prevention and/or |